Theraclion SA

Regulatory Filings • Mar 18, 2015

Theraclion announces an agreement with a German insurance company to cover breast fibroadenoma treatment with Echopulse® for up to half a million Germans

Agreement with BKK Verkehrsbau Union Expands Patient Access to Echotherapy in Germany

Malakoff, FRANCE – March 18, 2015 – THERACLION (Alternext, FR0010120402 - ALTHE), a company specializing in leading-edge medical equipment for echotherapy, today announces that more health insurance companies have subscribed to the coverage plan for echotherapy. Amongst those companies is the Betriebskrankenkasse Verkehrsbau Union (BBK VBU) which will now cover treatment with the Echopulse® system for its members with fibroadenomas, the most common form of benign breast lesions. Echopulse® combines high-intensity focused ultrasound (HIFU) and ultrasound imaging to enable accurate, non-invasive treatment of tumors, eliminating scaring and the need for general anesthesia.

BKK VBU, based in Berlin, covers more than 410,000 individuals in 30 branches throughout Germany. The BKK VBU reimbursement agreement comes in addition to a previous contract, announced in September 2014, between BKK Continentale and Marienhospital in Bottrop, Germany (find the press release online).

Managed by the Gesundheitsverbund Nord, the integrated care contract was submitted to the Bundesversicherungsamt (Federal Insurance Office) at the end of 2014 and has successfully passed the required legal approval period without any requests for change, granting patients throughout Germany who are members of partnering insurance companies free access to this non-surgical treatment.

"We strive to provide our members with access to the most innovative treatments. We are pleased to add echotherapy to our coverage list, giving our female members who suffer from breast fibroadenomas the ability to receive a gentler treatment option," says Andrea Galle, CEO of BKK BVU.

With now three health insurance policies (BKK Continentale, BKK Schleswig-Holstein, BKK BVU) offering reimbursement in Germany, covering up to half a million Germans for the non-invasive treatment of breast fibroadenomas, Theraclion accelerates its growth in Germany.

"We are building a plan with our partner GVN to expand our reach to millions of women shortly," says David Caumartin, Theraclion CEO. "We know this is our most important strategic imperative to accelerate our business expansion."

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris Mnemonic: ALTHE - ISIN Code: FR0010120402

Contacts:

Theraclion NewCap CEO Emmanuel Huynh / Sophie Boulila Phone: +33 (0)1 55 48 90 70 Phone: +33 (0)1 44 71 94 91 david.caumartin@theraclion.com theraclion@newcap.fr

ALIZE RP

Press relations Caroline Carmagnol / Valentine Boivin Phone: + 33 (0) 1 44 54 36 63 theraclion@alizerp.com

David Caumartin Financial Communications & Investor Relations